BullFrog AI Holdings Inc. has announced that data from its proprietary bfLEAP® platform will be presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 9. The study, conducted in collaboration with Eleison Pharmaceuticals and the Moffitt Cancer Center, utilized the bfLEAP® platform to analyze pancreatic cancer trial data and identified an almost threefold increase in mean survival from control to treatment arms. The research also highlighted the platform's ability to identify treatment effect heterogeneity and potential early predictors of outcomes in pancreatic cancer. The findings will also be published in the Journal of Clinical Oncology supplement corresponding to the symposium.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BullFrog AI Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9620116-en) on January 06, 2026, and is solely responsible for the information contained therein.